Reuters logo
BRIEF-Circassia Pharmaceuticals says H1 revenues up 65 pct to 18.3 mln pounds
September 27, 2017 / 6:11 AM / 2 months ago

BRIEF-Circassia Pharmaceuticals says H1 revenues up 65 pct to 18.3 mln pounds

Sept 27 (Reuters) - CIRCASSIA PHARMACEUTICALS PLC:

* H1 REVENUE OF 18.3 MILLION STG VERSUS 11.1 MILLION STG YEAR AGO

* H1 RESEARCH AND DEVELOPMENT EXPENDITURE OF 27.2 MILLION STG VERSUS 25.1 MILLION STG YEAR AGO

* H1 NIOX SALES GROWTH 19 PERCENT (8% AT CER 3 ) TO £13.1 MILLION​

* ‍IN KEY US MARKET, TARGETING A SUBSTANTIALLY LARGER CUSTOMER BASE THAN AT THIS TIME LAST YEAR​

* H1 GROUP LOSS BEFORE TAX OF 39.6 MILLION STG VERSUS LOSS OF 107.6 MILLION STG YEAR AGO

* ‍“ANTICIPATE ROBUST REVENUE GROWTH FOR BOTH NIOX AND TUDORZA”​

* ‍PARTNER ASTRAZENECA IS ON TRACK TO SUBMIT AN NDA FOR DUAKLIR IN FIRST HALF OF 2018​ Source text for Eikon: Further company coverage: (Bangalore.newsroom@thomsonreuters.com)

Our Standards:The Thomson Reuters Trust Principles.
0 : 0
  • narrow-browser-and-phone
  • medium-browser-and-portrait-tablet
  • landscape-tablet
  • medium-wide-browser
  • wide-browser-and-larger
  • medium-browser-and-landscape-tablet
  • medium-wide-browser-and-larger
  • above-phone
  • portrait-tablet-and-above
  • above-portrait-tablet
  • landscape-tablet-and-above
  • landscape-tablet-and-medium-wide-browser
  • portrait-tablet-and-below
  • landscape-tablet-and-below